ACE Gene and Cardiovascular Inflammation Risk | Decoding Inflammation

By Alberto Rivera, MD · 2026-06-16 · 5 min read

The Genetic Architecture of the Renin-Angiotensin System\n\nThe renin-angiotensin system (RAS) serves as a fundamental regulator of hemodynamic stability and electrolyte balance. At its core is the Angiotensin-Converting Enzyme (ACE), which converts angiotensin I into the potent vasoconstrictor angiotensin II. While physiologically necessary, genetic variations in the ACE gene can lead to an overproduction of angiotensin II, a molecule that acts not only as a pressor agent but also as a pro-inflammatory signaling molecule within the vascular wall.\n\n## Decoding the Insertion/Deletion (I/D) Polymorphism\n\nThe ACE gene, located on chromosome 17, exhibits a common polymorphism characterized by the presence (Insertion, I) or absence (Deletion, D) of a 287-base pair fragment in intron 16. Extensive clinical research has established that individuals homozygous for the deletion allele (the DD genotype) possess significantly higher levels of circulating ACE compared to those with the II or ID genotypes. This increase in enzymatic activity correlates directly with a heightened inflammatory state characterized by endothelial dysfunction and oxidative stress.\n\n## Cardiovascular Implications and Genomic Risk\n\nThe clinical consequences of the DD genotype are substantial. High ACE activity leads to increased angiotensin II, which stimulates the AT1 receptors, subsequently activating the Nuclear Factor-kappa B (NF-́ΙB) pathway. This pathway is responsible for the expression of various pro-inflammatory cytokines, including IL-6 and C-reactive protein (CRP). Consequently, carriers of the D allele, particularly the DD homozygous group, show a statistically significant predisposition to left ventricular hypertrophy, coronary artery disease, and carotid atherosclerosis. Understanding this genomic risk factor allows for the identification of patients who may be "hyper-responders" to inflammatory stimuli.\n\n## Clinical Application in Precision Medicine\n\nIn my practice at decodinginflammation.com, we emphasize that genetic markers like the ACE I/D polymorphism are not deterministic but are powerful risk modifiers. By identifying patients with the DD genotype early, clinicians can implement more aggressive primary prevention strategies. These may include the early introduction of ACE inhibitors or angiotensin II receptor blockers (ARBs), which counteract the genetic predisposition toward high ACE activity. Incorporating genomic data into cardiovascular risk models marks a pivotal shift toward personalized, proactive medicine that addresses the inflammatory roots of heart disease.